drugset / Trial / NCT00038636

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

NCT00038636

Phase 3 Completed 36 enrolled Abbott
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir

Timeline

Start
2000-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lopinavir/ritonavir Unknown
Background Ritonavir Other / unclassified